FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296010596> ?p ?o ?g. }

• W4296010596 endingPage "S943" @default.
• W4296010596 startingPage "S942" @default.
• W4296010596 abstract "Patients diagnosed with hematologic malignancies (HM) have a higher risk of developing subsequent solid tumors, such as melanoma. Patients with HM were mostly excluded from clinical trials but could derive less benefit from immune checkpoint inhibition due to disease or treatment-related T- or B-cell dysfunction. All advanced stage IIIc and IV melanoma patients treated with anti-PD-1 or ipilimumab-nivolumab between 2015 and 2021 were included from the prospective nationwide Dutch Melanoma Treatment Registry. Progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) were analyzed for patients with HM (HM+) and without HM (HM-). A cox model was used to account for confounders associated with PFS and OS. Fifty-seven HM+ patients and 2506 HM- patients were included. Twenty-two patients were diagnosed with leukemia, 26 with malignant lymphoma, three with multiple myeloma, and six had a different type of HM. Forty-four percent received curative treatment for their HM. In the anti-PD-1 cohort, median PFS was 2.8 months for HM+ and 9.9 months for HM- (p=0.01). MSS was 41.2 months for HM+ and 58.1 months for HM- (p=0.00086). In multivariable analysis, the presence of a HM was significantly associated with a higher risk of melanoma progression (HRadj 1.68; 95%CI 1.24-2.29; p<0.001) and death (HRadj 1.76; 95%CI 1.25-2.47; p<0.001). Median PFS, OS, and MSS for anti-PD-1 and ipilimumab-nivolumab can be seen in the table.Table: 859PMedian progression-free survival, overall survival, and melanoma-specific survival in months, stratified by hematologic malignancy and treatment typeMedian PFS in months (95% CI)Median OS in months (95% CI)Median MSS in months (95% CI)Anti-PD-1 and HM+ (n=46)2.8 (2.6-7.3)12.8 (6.2-NR)41.2 (12.8-NR)Anti-PD-1 and HM (n=1717)9.9 (8.6-11.8)31.0 (28.5-35.0)58.1 (47.5-NR)Ipilimumab-nivolumab and HM+ (n=11)2.3 (2.0-NR)4.6 (2.4-NR)4.6 (2.4-NR)Ipilimumab-nivolumab and HM- (n=789)6.9 (5.5-9.2)31.7 (22.1-39.0)46.1 (33.4-NR) Open table in a new tab Patients with hematologic malignancy and advanced melanoma show significantly worse melanoma-related survival than patients with advanced melanoma alone. Larger numbers of patients are needed to look into the different subtypes of HM." @default.
• W4296010596 created "2022-09-17" @default.
• W4296010596 creator A5009376752 @default.
• W4296010596 creator A5013384569 @default.
• W4296010596 creator A5018011096 @default.
• W4296010596 creator A5027916501 @default.
• W4296010596 creator A5028034089 @default.
• W4296010596 creator A5028513835 @default.
• W4296010596 creator A5031300611 @default.
• W4296010596 creator A5031506026 @default.
• W4296010596 creator A5031622855 @default.
• W4296010596 creator A5040090994 @default.
• W4296010596 creator A5049383618 @default.
• W4296010596 creator A5050091697 @default.
• W4296010596 creator A5052963680 @default.
• W4296010596 creator A5061565581 @default.
• W4296010596 creator A5073746782 @default.
• W4296010596 creator A5081011064 @default.
• W4296010596 creator A5085881684 @default.
• W4296010596 creator A5087475694 @default.
• W4296010596 creator A5091312431 @default.
• W4296010596 date "2022-09-01" @default.
• W4296010596 modified "2023-10-01" @default.
• W4296010596 title "859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma" @default.
• W4296010596 doi "https://doi.org/10.1016/j.annonc.2022.07.985" @default.
• W4296010596 hasPublicationYear "2022" @default.
• W4296010596 type Work @default.
• W4296010596 citedByCount "0" @default.
• W4296010596 crossrefType "journal-article" @default.
• W4296010596 hasAuthorship W4296010596A5009376752 @default.
• W4296010596 hasAuthorship W4296010596A5013384569 @default.
• W4296010596 hasAuthorship W4296010596A5018011096 @default.
• W4296010596 hasAuthorship W4296010596A5027916501 @default.
• W4296010596 hasAuthorship W4296010596A5028034089 @default.
• W4296010596 hasAuthorship W4296010596A5028513835 @default.
• W4296010596 hasAuthorship W4296010596A5031300611 @default.
• W4296010596 hasAuthorship W4296010596A5031506026 @default.
• W4296010596 hasAuthorship W4296010596A5031622855 @default.
• W4296010596 hasAuthorship W4296010596A5040090994 @default.
• W4296010596 hasAuthorship W4296010596A5049383618 @default.
• W4296010596 hasAuthorship W4296010596A5050091697 @default.
• W4296010596 hasAuthorship W4296010596A5052963680 @default.
• W4296010596 hasAuthorship W4296010596A5061565581 @default.
• W4296010596 hasAuthorship W4296010596A5073746782 @default.
• W4296010596 hasAuthorship W4296010596A5081011064 @default.
• W4296010596 hasAuthorship W4296010596A5085881684 @default.
• W4296010596 hasAuthorship W4296010596A5087475694 @default.
• W4296010596 hasAuthorship W4296010596A5091312431 @default.
• W4296010596 hasConcept C121608353 @default.
• W4296010596 hasConcept C126322002 @default.
• W4296010596 hasConcept C143998085 @default.
• W4296010596 hasConcept C2776364478 @default.
• W4296010596 hasConcept C2777658100 @default.
• W4296010596 hasConcept C2777701055 @default.
• W4296010596 hasConcept C2780030458 @default.
• W4296010596 hasConcept C2781433595 @default.
• W4296010596 hasConcept C502942594 @default.
• W4296010596 hasConcept C50382708 @default.
• W4296010596 hasConcept C71924100 @default.
• W4296010596 hasConcept C90924648 @default.
• W4296010596 hasConceptScore W4296010596C121608353 @default.
• W4296010596 hasConceptScore W4296010596C126322002 @default.
• W4296010596 hasConceptScore W4296010596C143998085 @default.
• W4296010596 hasConceptScore W4296010596C2776364478 @default.
• W4296010596 hasConceptScore W4296010596C2777658100 @default.
• W4296010596 hasConceptScore W4296010596C2777701055 @default.
• W4296010596 hasConceptScore W4296010596C2780030458 @default.
• W4296010596 hasConceptScore W4296010596C2781433595 @default.
• W4296010596 hasConceptScore W4296010596C502942594 @default.
• W4296010596 hasConceptScore W4296010596C50382708 @default.
• W4296010596 hasConceptScore W4296010596C71924100 @default.
• W4296010596 hasConceptScore W4296010596C90924648 @default.
• W4296010596 hasLocation W42960105961 @default.
• W4296010596 hasOpenAccess W4296010596 @default.
• W4296010596 hasPrimaryLocation W42960105961 @default.
• W4296010596 hasRelatedWork W1963731933 @default.
• W4296010596 hasRelatedWork W2745358348 @default.
• W4296010596 hasRelatedWork W2888298425 @default.
• W4296010596 hasRelatedWork W2947988614 @default.
• W4296010596 hasRelatedWork W2955428297 @default.
• W4296010596 hasRelatedWork W2963333658 @default.
• W4296010596 hasRelatedWork W2969687411 @default.
• W4296010596 hasRelatedWork W3215044659 @default.
• W4296010596 hasRelatedWork W4319163597 @default.
• W4296010596 hasRelatedWork W4361939003 @default.
• W4296010596 hasVolume "33" @default.
• W4296010596 isParatext "false" @default.
• W4296010596 isRetracted "false" @default.
• W4296010596 workType "article" @default.